Open AccessInduction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives
Author(s) -
Allam Magdy Mohamed,
Elzawawy Hanaa Tarek Hussein
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1827
Subject(s) - medicine , vitiligo , azathioprine , autoimmune thyroiditis , refractory (planetary science) , dermatology , thyroiditis , immunology , disease , physics , astrobiology
Key Clinical Message The autoimmune polyglandular syndrome is a sequential chain of autoimmune events. Whenever diagnosed, the clinician's target should be induction of remission and if possible hindering its progression especially if associated with refractory vitiligo, resistant Grave's, or unexplained hyperglycemia in T1DM. Azathioprine could be used for induction of remission in autoimmune polyglandular syndrome type three especially with vitiligo and autoimmune thyroiditis.